C4 Therapeutics (CCCC) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 1.6% versus a loss of 20.0%. Over five years, CCCC leads with a -93.2% price change compared with -97.8% for XFOR. C4 Therapeutics is the larger company by market cap ($325.7 million vs $306.3 million), about 1.1 times the size, while X4 Pharmaceuticals is growing revenue faster (+150.0% vs +1.0%).
C4 Therapeutics converts more of its revenue into profit, with a net margin of -292.1% versus -1218.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | XFOR |
|---|---|---|
| Share price | $2.48 | $3.00 |
| Market cap | $325.67M | $306.34M |
| 1-day change | +1.64% | +1.35% |
| YTD return | +29.84% | -25.00% |
| 1-year return | +1.64% | -20.00% |
| 5-year return | -93.23% | -97.79% |
| P/E ratio (TTM) | — | 5.45 |
| EPS (TTM) | $-0.63 | $0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $35.95M | $6.50M |
| Revenue growth (YoY) | +1.02% | +150.00% |
| Net income (latest FY) | $-104.99M | $-79.20M |
| Gross margin | — | 11.43% |
| Operating margin | -320.53% | -1336.66% |
| Net margin | -292.08% | -1218.45% |
| 52-week high | $5.17 | $4.83 |
| 52-week low | $1.69 | $2.43 |
| Distance from 52-week high | -52.03% | -37.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +404.03% | +286.67% |
| Average volume | 2.57M | 877.70K |
| Shares outstanding | 131.32M | 102.11M |
| Employees | 104 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed XFOR by 21.6 percentage points over the past year.
- C4 Therapeutics is more profitable, keeping -292.1 cents of every revenue dollar as net income versus -1218.4 cents for X4 Pharmaceuticals.
- X4 Pharmaceuticals grew revenue faster in its latest fiscal year (+150.00% vs +1.02%).
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
CCCC vs XFOR FAQ
Which is bigger, C4 Therapeutics or X4 Pharmaceuticals?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $306.34M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, CCCC or XFOR?
CCCC returned +1.64% over the past 12 months, compared with -20.00% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.